Dianthus Therapeutics, Inc. $DNTH Stock Sold by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC trimmed its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 12.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,620 shares of the company’s stock after selling 8,932 shares during the period. Dianthus Therapeutics makes up approximately 1.1% of Moody Aldrich Partners LLC’s investment portfolio, making the stock its 26th largest holding. Moody Aldrich Partners LLC owned 0.12% of Dianthus Therapeutics worth $5,778,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. ABS Investment Management LLC acquired a new stake in Dianthus Therapeutics in the second quarter worth about $194,960,000. PNC Financial Services Group Inc. increased its stake in Dianthus Therapeutics by 0.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after buying an additional 139 shares during the period. GAMMA Investing LLC increased its stake in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after buying an additional 254 shares during the period. First Horizon Corp acquired a new position in Dianthus Therapeutics during the 1st quarter valued at about $32,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Dianthus Therapeutics by 75.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock worth $93,000 after buying an additional 453 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Anne McGeorge sold 7,750 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the sale, the director owned 1,250 shares in the company, valued at $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer owned 65,292 shares in the company, valued at $7,058,718.12. This represents a 71.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 242,429 shares of company stock valued at $26,118,913. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Stock Up 3.5%

NASDAQ:DNTH opened at $82.31 on Thursday. Dianthus Therapeutics, Inc. has a 1-year low of $32.28 and a 1-year high of $117.88. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of -19.83 and a beta of 1.35. The stock has a fifty day simple moving average of $93.92 and a 200 day simple moving average of $84.17.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DNTH. Truist Financial upped their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Wedbush boosted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Raymond James Financial restated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They set an “overweight” rating and a $135.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus price target of $128.54.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.